title: Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
abstract: Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541 patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS) curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1), secondary toxicity (Tox2), time without symptom and toxicity (TWiST), and relapse (Rel). Areas under survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT increased, but not significantly, TWiST (+2. 4 months in AUC, P =.17) and decreased Rel (-3 months, P <.01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for OS, 39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a significant benefit in DFS (AUC 28.8 versus 24.9 months, P <.01) but not in OS (AUC 37.3 versus 36 months, P =.27). Sensitivity analysis, performed by varying QOL coefficients, demonstrated significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients, a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in these patients with adverse prognostic factors in the first CR, even after adjusting for QOL using the Q-TWiST method. (Blood. 2000;95:3687-3692)
authors.affiliation: Département d'information hospitalier and Service d'hématologie clinique Hôpital Henri Mondor, AP-HP, Créteil, France.
authors.forename: N
authors.initials: N
authors.lastname: Mounier
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.forename: B F
authors.initials: BF
authors.lastname: Cole
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: C
authors.initials: C
authors.lastname: Sebban
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: C
authors.initials: C
authors.lastname: Ravoet
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.forename: F
authors.initials: F
authors.lastname: Reyes
authors.forename: E
authors.initials: E
authors.lastname: Lepage
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000523:psychology* / Q000628:therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D015999:Multivariate Analysis; D011241:Prednisone / Q000008:administration & dosage; D011788:Quality of Life; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D014751:Vindesine; D011241:Prednisone